Greetings and welcome to the Entera Bio's Fourth Quarter and Year-End 2021 Earnings Call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.

I would now like to turn the call over to Ramesh Ratan, Chief Financial Officer. Thank you. You may begin..

Good morning, and welcome to the call. Joining me on today's call are Spiros Jamas, our CEO; Arthur Santora, our Chief Medical Officer; and Phillip Schwartz, our Founder and President of R&D. A press release announcing Entera's financial and operating results for the full-year ended December 31, 2021, was issued this morning.

For those of you who have not yet seen it, it's available on the Investors section of our website, www.enterabio.com. On our call this morning, we will share with you a business update and review of our financial results, which will be followed by a question-and-answer session.

Before we begin our prepared remarks, I would like to remind you that various statements we make during this call about the Company's future results of operations and financial position, our interpretation of data from the recently completed Phase 2 clinical trials of EB613, our business strategy, and plans and objectives for our future operations are considered forward-looking statements within the meaning of the Federal securities laws.

Our forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.

Specifically, developments related to the COVID-19 pandemic continue to evolve and the extent to which the pandemic will impact us in the future, will depend on the duration and magnitude of such impact, and on numerous factors that we may not be able to accurately predict.

These risks are described more fully in our SEC filings and are available on the SEC's EDGAR system and on our website. We encourage all investors to read our SEC filings.

All the information we provide on this conference call is provided only as of today, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. Finally, please be advised that today's call is being recorded and webcast.

I will now turn the call over to Spiros Jamas..

Thank you, Ramesh, and thanks everyone for joining the call this morning. I joined Entera because of the performance of the company's validated technology platform that enabled the oral delivery of protein therapeutics and the talented, dedicated and hardworking team.

We have hit several key milestones that have generated value for our shareholders and confirm my confidence in our team and technology and believe we are on the path to creating a very valuable business.

In the second quarter of 2021, we reported the ultimate and scientific validation that our Phase 2 clinical study of EB613, our oral PTH product, for the treatment of osteoporosis met its primary and key secondary endpoints.

There is a linear and statistically significant dose response for PTH dose and the key anabolic biochemical markers P1NP, and osteocalcin, with a P value of less than 0.001 and bone mineral density, the clinical marker of bone mass and strength.

The three months biomarker results, was accepted and presented at the leading Clinical Bone Disease Conference, the ASBMR last October 2021.

Our six months bone mineral density results were accepted and presented by our Chief Medical Officer, Art Santora, as a prestigious Late Breaker, oral presentation also at ASBMR this is important peer reviewed presentation of our studies.

I believe these data will support business development efforts and will generate future value through strategic collaborations and partnerships. Separately, the data from our Phase 2a study of EB613 in hyperparathyroidism patients was published in the Journal of Bone Mineral Research.

We are focused on leveraging the platform technology to create additional value either through proprietary products, such as EB613 and EB612 that can be developed either by Entera alone or in collaboration with a partner or applying our technology to another company's compounds, such as what we are doing in our collaboration with Amgen.

In addition to our expanding internal pipeline, as part of our business development efforts, we have signed material transfer agreements with multiple biopharma companies to demonstrate the feasibility of Entera's platform for oral delivery of various proprietary target compounds.

These options potentially enable multiple partnering opportunities that can generate non-dilutive funding, news flow, and allow the company to share in the future value of multiple de-risked assets. 2021 was definitely a year of execution.

We ended 2021 with a successful end of Phase 2 meeting with the FDA, where we reviewed the Phase 2 osteoporosis data, proposed Phase 3 protocol, and other requirements for an NDA submission. The meeting was positive and confirmed the use of bone mineral density as the primary Phase 3 endpoint.

We are incorporating input from the FDA into the Phase 3 study design and we are projecting a second half of 2022 start of the Phase 3 study. We strengthened our balance sheet and I'm pleased to report $24.9 million at year-end 2021. I'd like to give you a snapshot of why we think EB613 is a tremendous opportunity in the osteoporosis market.

EB613 is an oral formulation of human parathyroid hormone 1-34 or PTH and is positioned to be the first oral once-a-day bone building osteoanabolic product to treat osteoporosis patients.

The successful Phase 2 study has brought EB613 one step closer to potentially becoming available to the estimated 200 million people affected by osteoporosis worldwide. In the U.S. alone, 54 million Americans have osteoporosis or low bone mass, which places them at an increased risk for developing osteoporosis.

One in two women and one in four men over 50 years of age will break a bone due to osteoporosis. In a therapeutic market this large, estimated at over $7 billion annually today, surprisingly there are only three effective bone building treatments available.

They are Forteo Teriparatide, Tymlos Abaloparatide, and Evenity Romosozumab, all three are injectables. This may be one reason why less than 5% of people living with osteoporosis are treated with anabolic drugs. These injectables are also quite pricey at a cost of between $20,000 and $35,000 per year in the U.S.

We believe that a safe and effective oral bone building drug likely EB613 may significantly expand the number of patients being treated.

More than 90% of all osteoporosis patients who are taking any form of pharmaceutical are being treated with an oral agent, an oral bone building agent may not only get conversions from current injectable drugs, but may also attract many new patients currently not receiving any treatment.

This assumption was borne out in a research study we commissioned with an independent market research firm, which found that patients, physicians, payers and providers are seeking more cost-effective oral solutions. Aside for the more patient-friendly oral delivery as in an oral drug, EB613 can be far more cost effective than injectables.

We believe Entera has a multi-billion dollar opportunity here by treating new patients at high-risk of fracture. We estimate there is a realizable opportunity for a 10% or greater market penetration for both treated and currently untreated patients.

Even at a discount to current injectable therapies, this should translate to a potential multi-billion dollar market opportunity. I will now turn it over to Phillip to review EB612, additional progress with our platform, and various business development activities..

X in October 2021. Additionally, new data were announced suggesting Entera's platform orally delivers human growth hormone, shared in a poster presentation at the 31st Annual European Pharma Congress in London in 2021.

From a business development perspective, we have increased our efforts to leverage our technology platform, and have ongoing dialogues with several companies that are exploring the use of our oral delivery platform, the fair injectable product candidates.

We also continue to focus on the development of our platform as it relates to the evaluation of new API's, and believe that these efforts have the potential to generate value through either additional validation of our technology platform and/or through potential business development activities.

Given the significant increase in active material transfer agreement that we have executed, we believe that some of these will result in more extensive long-term collaboration and licensing transactions. I now turn it over to Ramesh, our Chief Financial Officer for the United States..

Thank you, Phillip. Revenues for the year ended December 31, 2021, were $571,000, as compared to $365,000, for the year ended December 31, 2020. For 2021 and 2020 a majority of our revenues were attributable to research and development or R&D services provided to Amgen under the Amgen agreement and other MTA agreements.

Cost of revenues for the year ended December 31, 2021, and December 31, 2020, were $373,000 and $300,000 respectively and we're comprised of salaries and related expenses in connection with R&D services provided to Amgen and other MTA agreements.

Total operating expenses for the year ended December 31, 2021, were $12.4 million and included $6.7 million in research and development expenses, and $5.7 million in general and administrative expenses.

Total operating expenses for the year ended December 31, 2020, were $11.2 million and included $6.4 million in research and development, and $4.8 million in general and administrative expenses.

Research and development expense for the year ended December 31, 2021, consisted primarily of headcount related cost and external costs related to the conduct of the recently completed EB613 Phase 2 clinical trial.

General and administrative expense for the year ended December 31, 2021, were primarily made up of salary and related expenses, including share-based compensation, professional fees, D&O insurance, and legal fees. Net loss for the year ended December 31, 2021, was $12.2 million or $0.47 per ordinary share.

For the year ended December 31, 2020, the net loss was $11.2 million or $0.67 per ordinary share diluted. As of December 31, 2021, Entera had cash and cash equivalents of $24.9 million and in our 10-K that we filed today, we will report approximately $21.7 million in cash and cash equivalents as of March 1, 2022.

Based on current operating plans, we expect our cash position will be sufficient to fund operations into the fourth quarter of 2022. I'll now turn the call back to Spiros for concluding remarks, before we go to Q&A..

Thanks, Ramesh. The successful completion of the Phase 2 osteoporosis study was a major milestone, given the extraordinary challenges related to the COVID-19 pandemic. And I want to thank the patients, investigators, consultants, and the entire Entera team for their hard work and persistence in rigorously executing this clinical study.

I also want to thank our shareholders and directors and consultants for their support of Entera's mission. 2021 was an extraordinary execution year with our lead program progressing to Phase 3 for this multi-billion dollar market. We expect 2022 will also be a year of execution and meaningful deals.

We're off to a good start this year with a key patent filing, and numerous business development and strategic partnering discussions. Entera is entering very exciting times with many big catalysts in the coming year. Thanks to everyone for taking the time this morning, listening to our review of operations.

We look forward to providing you with regular updates on our progress in the coming months. Have a good day. We will now take questions..

Thank you. We will now be conducting a question-and-answer session. [Operator Instructions]. Our first question comes from the line of Kalpit Patel with B. Riley. Please proceed with your questions..

Yes, hi, good morning. Thanks for taking our questions. Spiros, first can you confirm that you will be titrating to the 2.5 milligram dose of EB613 in the upcoming Phase 3, and then, if you are titrating, can you give us additional color on perhaps how you're designing this trial to mitigate any risks for not showing non-inferiority against Forteo.

I know, there were some differences in efficacy between the titrated and non-titrated dosing groups in the Phase 2.

So are there any certain steps that you might be taking to offset these efficacy differences potentially in the Phase 3?.

Yes, hi Kalpit. Yes, thanks for your question. Yes, so in terms of the titration regimen, we've really tried to learn as much as we can from the Phase 2 and apply that to the Phase 3 study to sort of de risk the impact of the titration.

So the Phase 2 study, as you know, titrated over a very prolonged period over two months to go from the 1.5 milligram dose up to 2.5 milligram dose. And it took us two months to get to the 2.5 milligram dose. And then it was only for the four months out of the six that patients were on the maximal of 2.5 milligram dose.

And so what we're instituting in the Phase 3 study, we're still doing the same titration, going from 1.5 to the 2.5 milligram dose, but we're going to institute a more accelerated titration just over two weeks, versus the two months of the -- in the Phase 2 study.

So based on our review of the PK data and our Phase 2 results, we feel that that titration will achieve -- will achieve what we need.

The other good thing about the titration, as we saw in our Phase 2 study that in the titrated group, only one patient dropped out, so there was a very high retention about over 90% of patients that were titrated up to 2.5 milligrams, who remained in the study, which was a very good sign of the tolerability for those patients, even though they were at a 2.5 milligram dose for the full course of the study.

And so and then one other element is that the Phase 3 study is a 12-month study and so patients will be on the full 2.5 milligram dose for essentially the entire 12-month period and having this very rapid titration up to the 2.5 milligram dose.

Does that --?.

Sorry, go ahead..

No, go ahead..

No, I think that's very helpful.

I just -- I was going to ask, what's the status of the Phase 3, are there any additional gating factors before you actually commence the trial? I think previously, you've guided to initiate in third quarter of this year, is it still fair to assume that those timelines remain on track?.

Yes, sure. Yes, the timelines that we were guiding to second half of this year. So it could be a third quarter or fourth quarter, and definitely for second half of this year. And some of the activities are going on. I mean, we've signed up the CRO that is going to be working with us on this study. We're very busy in sort of identifying sites.

And on the operational side, and getting that aspect of the study operations are going up, up and running. Then we also, there are some refinements to the protocol that are based on our end of Phase 2 meeting with FDA.

FDA has made some very useful suggestions for the study design, which I think would improve the Phase 3 study and so we're going through the process of updating the Phase 3 protocol. And once that, we have the final Phase 3 protocol, obviously we'll be going with that and we'll update the market when we have the final Phase 3 protocol.

It's also assuming about between 600 to 800 patients is still the current assumption for the Phase 3 study..

Okay, fair enough.

And how should we think about business development opportunities for 613, I think you mentioned some interest for 612, but what about the lead program, there was some regional interests that you mentioned in the past for 613, are those conversations still ongoing?.

Oh, yes, now very much ongoing, yes, there is significant sort of regional especially sort of Asian interests for osteoporosis, a very large market and those discussions are progressing extremely well.

And we've also though, as we announced today, we've recruited Torreya Capital to work with us on the partnering -- global partnering for osteoporosis asset. We think they'll put us in the best position to get to already have our -- the best partnership for our program.

And that will really, ultimately help us get to the finish line of an approved product so globally. And so we're really excited about the Torreya coming on board and they're obviously helping a lot in the strategic alliance and partnering efforts.

There's also substantial interest, as Phillip mentioned on our hyperparathyroidism asset, there's a lot of interest, a lot of companies with the presence in the orphan diseases space, have a lot of interest, and we also -- there's a high possibility of a collaboration in that space as well..

Okay.

And one final question, Spiros, is the GLP-2 program the next program that we should expect you to enter into the clinic? How should we think about timelines for advancement on this one?.

Yes. We will be sort of announcing or having another sort of Investor Day to discuss our platform.

And our next what next API, we will select for going through, we've put together a very seasoned scientific advisory committee that is helping us select our next sort of API that offers the best sort of potential between our platform and the properties of the API. So it may be GLP-2, but there are some other, also very exciting possibilities.

The other GLPs that also offer maybe even bigger potential and then much bigger commercial opportunity. And so what we'll -- we're going through that process of prioritizing which one, which next sort of API, we will select from our next program.

So expect to have an update probably in the first half of this year where we will update our investors and the market..

Thank you. [Operator Instructions]. Our next question is come from the line of Nathan Weinstein with Aegis Capital. Please proceed with your question..

Thank you and good morning, Spiros and to the entire team, congrats on the progress. I look the business in so many different areas. I guess just a couple questions for me. Firstly, the revenue line continues to tick higher.

Do you think you can make any directional comments on where that could go? And then does that include both the Amgen and new partnerships as well?.

Yes, great. Hi, Nathan. Great question. Yes, good catch, our revenue line is picking in the right direction. And that is the bulk of the revenues are from Amgen's payments to Entera's, via Amgen covers all Entera costs related to the Amgen collaboration. So there's no funding, that Entera contributes towards that partnership that is all covered by Amgen.

But we have also been getting a number of new material transfer agreements, which are funded by the companies that we negotiating with. So those companies are paying us to do these initial feasibility studies.

And so there is that uptick in revenue is also related to the higher number of MTAs that we've signed for getting that that initial sort of MTA funding, and so that is a good, kind of a good mark.

I would say that we expect to be entering into a next large collaboration this year on a new program, sort of very similar to Amgen that's very de-risk, but that will provide significant funding to Entera..

Great, thank you Spiros. And just one question here on EB613.

In the studies to-date, could you just remind us what if any background therapies patients were on and then what might be allowed or not in the Phase 3 study?.

Yes, they were no, I believe the patients could not be on any anabolic drugs for a number of years before for quite a long period before they were enrolled in the study. And the same is the case for the Phase 3.

I'll ask Art Santora, Chief Medical Officer, to just add a little more information on the, what background therapies, patients were on we're not on the Phase 2 and then also how we're handling that for the Phase 3, if you could provide that..

Yes, sure. All the patients had nutritional support in terms of supplemental dietary calcium that they needed to and a standard dose of Vitamin D3. That's the nutrient Vitamin D3 not an activated analog. And as Spiros pointed out, patients couldn't have been on active therapy at the time they started this study.

However, you sort of stayed bisphosphonates as long as it's a number of years in the past was allowed. That's very common situation that we run into clinically. No immediate transitions from a bisphosphonate to EBP05 would be allowed. The same would be in Phase 3.

These would be very similar population who would be candidates for an osteoanabolic it's currently approved. And they wouldn't be transitioning directly from a prior therapy like bisphosphonate or denosumab to the intervention in the trial. There'll be a gap of probably in the order of two to three years depending on the drug..

Okay, okay, fine. So, thank you for the detail there and I think that's it for me for now and congrats again on the progress. It's nice to see you guys developing the businesses so much..

Thanks, Nathan..

Thank you. [Operator Instructions]. There are no further questions at this time. I would now like to turn the call back over to Spiros Jamas for any closing comments..

Good morning, everyone. Thank you so much for calling in for our earnings call. As you can see, we were really on the verge of some big catalysts for Entera, for expanding Entera's business and using our platform as a huge value driver that always really believe can become.

We have some very solid clinical milestones this year with progression to Phase 3. And we'll be keeping you updated on both of our lead program, but also our expanding opportunities with our platform. So thank you very much. Have a good day..

This does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day..